https://doi.org/10.1016/j.ijid.2020.10.101Get rights and content
Highlights
•
Anti-CCR5 humanized monoclonal antibody restored CD8 counts in COVID patients.
•
Inversely correlated with decreases in plasma viral load (pVL) by day 14.
•
CCL5/RANTES up 3–5-fold in mild/moderate patients and >100-fold in critical ones.
•
First report of highly sensitive, quantitative pVL by ddPCR in COVID patients.
•
Statistically significant drop in IL-6 by day 14 of treatment.
Abstract
Objective
Infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is now a global pandemic. Emerging results indicate a dysregulated immune response. Given the role of CCR5 in immune cell migration and inflammation, we investigated the impact of CCR5 blockade via the CCR5-specific antibody leronlimab on clinical, immunological, and virological parameters in severe COVID-19 patients.
Methods
In March 2020, 10 terminally ill, critical COVID-19 patients received two doses of leronlimab via individual emergency use indication. We analyzed changes in clinical presentation, immune cell populations, inflammation, as well as SARS-CoV-2 plasma viremia before and 14 days after treatment.
Results
Over the 14-day study period, six patients survived, two were extubated, and one discharged. We observed complete CCR5 receptor occupancy in all donors by day 7. Compared with the baseline, we observed a concomitant statistically significant reduction in plasma IL-6, restoration of the CD4/CD8 ratio, and resolution of SARS-CoV2 plasma viremia (pVL). Furthermore, the increase in the CD8 percentage was inversely correlated with the reduction in pVL (r = −0.77, p = 0.0013).
Conclusions
Our study design precludes clinical efficacy inferences but the results implicate CCR5 as a therapeutic target for COVID-19 and they form the basis for ongoing randomized clinical trials.
